Prostate brachytherapy postimplant dosimetry: Seed orientation and the impact of dosimetric anisotropy in stranded implants

Medical Physics

Volumn 39, Issue 2, 2012, Pages 721-731

  Chng, Nicholas ^a   Spadinger, Ingrid ^a   Rasoda, Rosey ^b   Morris, W James ^a   Salcudean, Septimiu ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

anisotropy; post implant dosimetry; prostate brachytherapy; quality assurance

Indexed keywords

ANISOTROPY; DOSIMETRY; ONCOLOGY; QUALITY ASSURANCE; RADIOTHERAPY; UROLOGY;

CO-ORDINATE SYSTEM; CONTRIBUTING FACTOR; DOSE DISTRIBUTIONS; DOSIMETRIC IMPACT; MID-SAGITTAL PLANES; POSTIMPLANT DOSIMETRY; PROSTATE BRACHYTHERAPY; STATISTICALLY SIGNIFICANT DIFFERENCE;

COMPUTERIZED TOMOGRAPHY;

EID: 84856951069     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.3671921     Document Type: Article

References (37)

1. W. J. Morris, M. Keyes, D. Palma, I. Spadinger, M. R. McKenzie, A. Agranovich, T. Pickles, M. Liu, W. Kwan, J. Wu, E. Berthelet, and H. Pai, Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer., Urology 73, 860-865; discussion 865-867 (2009). 10.1016/j.urology.2008.07.064
2. J. Crook, J. Borg, A. Evans, A. Toi, E. P. Saibishkumar, S. Fung, and C. Ma, 10-year experience with I-125 prostate brachytherapy at the Princess Margaret hospital: Results for 1,100 patients., Int. J. Radiat. Oncol., Biol., Phys. 80, 1329-1329 (2010). 10.1016/j.ijrobp.2010.04.038
3. A. V. Taira, G. S. Merrick, W. M. Butler, R. W. Galbreath, J. Lief, E. Adamovich, and K. E. Wallner, Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy., Int. J. Radiat. Oncol., Biol., Phys. 79, 1336-1342 (2010). 10.1016/j.ijrobp.2010.01.005
4. S. Nag, D. Beyer, J. Friedland, P. Grimm, and R. Nath, American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer., Int. J. Radiat. Oncol., Biol., Phys. 44, 789-799 (1999). 10.1016/S0360-3016(98)00452-0
5. M. J. Zelefsky, D. A. Kuban, L. B. Levy, L. Potters, D. C. Beyer, J. C. Blasko, B. J. Moran, J. P. Ciezki, A. L. Zietman, T. M. Pisansky, M. Elshaikh, and E. M. Horwitz, Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation., Int. J. Radiat. Oncol., Biol., Phys. 67, 327-333 (2007). 10.1016/j.ijrobp.2006.08.056
6. R. G. Stock, N. N. Stone, A. Tabert, C. Iannuzzi, and J. K. DeWyngaert, A dose-response study for I-125 prostate implants., Int. J. Radiat. Oncol., Biol., Phys. 41, 101-108 (1998). 10.1016/S0360-3016(98)00006-6
7. M. A. Kollmeier, R. G. Stock, and N. Stone, Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality., Int. J. Radiat. Oncol., Biol., Phys. 57, 645-653 (2003). 10.1016/S0360-3016(03)00627-8
8. L. Potters, D. Huang, E. Calugaru, P. Fearn, L. Lee, and M. W. Kattan, Importance of implant dosimetry for patients undergoing prostate brachytherapy., Urology 62, 1073-1077 (2003). 10.1016/j.urology.2003.07.004
9. R. Nath, L. L. Anderson, G. Luxton, K. A. Weaver, J. F. Williamson, and A. S. Meigooni, Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM radiation therapy committee Task Group No. 43. American Association of Physicists in Medicine., Med. Phys. 22, 209-234 (1995). 10.1118/1.597458
10. R. Nath, W. S. Bice, W. M. Butler, Z. Chen, A. S. Meigooni, V. Narayana, M. J. Rivard, Y. Yu, and American Association of Physicists in Medicine, AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137., Med. Phys. 36, 5310-5322 (2009). 10.1118/1.3246613
11. J. F. Corbett, J. J. Jezioranski, J. Crook, T. Tran, and I. W. Yeung, The effect of seed orientation deviations on the quality of 125I prostate implants., Phys. Med. Biol. 46, 2785-2800 (2001). 10.1088/0031-9155/46/11/303
12. N. Chng, I. Spadinger, W. J. Morris, N. Usmani, and S. Salcudean, Prostate brachytherapy postimplant dosimetry: Automatic plan reconstruction of stranded implants., Med. Phys. 38, 327-342 (2011). 10.1118/1.3525839
13. J. E. Sylvester, P. D. Grimm, S. M. Eulau, R. K. Takamiya, and D. Naidoo, Permanent prostate brachytherapy preplanned technique: The modern Seattle method step-by-step and dosimetric outcomes., Brachytherapy 8, 197-206 (2009). 10.1016/j.brachy.2009.02.001
14. R. S. Sloboda, N. Usmani, J. Pedersen, A. Murtha, N. Pervez, and D. Yee, Time course of prostatic edema post permanent seed implant determined by magnetic resonance imaging., Brachytherapy 9, 354-361 (2010). 10.1016/j.brachy.2009.09.008
15. A. Tanabe, K. Fukumizu, S. Oba, T. Takenouchi, and S. Ishii, Parameter estimation for Von Mises-Fisher distributions., Comput. Stat. 22, 145-157 (2007). 10.1007/s00180-007-0030-7
16. R. E. Taylor and D. W. Rogers, An EGSnrc Monte Carlo-calculated database of TG-43 parameters., Med. Phys. 35, 4228-4241 (2008). 10.1118/1.2965360
17. M. J. Rivard, B. M. Coursey, L. A. DeWerd, W. F. Hanson, M. S. Huq, G. S. Ibbott, M. G. Mitch, R. Nath, and J. F. Williamson, Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations., Med. Phys. 31, 633-674 (2004). 10.1118/1.1646040
18. P. Lindsay, J. Battista, and J. Van Dyk, The effect of seed anisotrophy on brachytherapy dose distributions using 125I and 103Pd., Med. Phys. 28, 336-345 (2001). 10.1118/1.1350674
19. O. Chibani, J. F. Williamson, and D. Todor, Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants., Med. Phys. 32, 2557-2566 (2005). 10.1118/1.1897466
20. W. J. Morris, M. Keyes, D. Palma, M. McKenzie, I. Spadinger, A. Agranovich, T. Pickles, M. Liu, W. Kwan, J. Wu, V. Lapointe, E. Berthelet, H. Pai, R. Harrison, W. Kwa, J. Bucci, V. Racz, and R. Woods, Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer., Int. J. Radiat. Oncol., Biol., Phys. 73, 1432-1438 (2009). 10.1016/j.ijrobp.2008.07.042
21. W. J. Morris, R. Halperin, and I. Spadinger, Point: The relationship between postimplant dose metrics and biochemical no evidence of disease following low dose rate prostate brachytherapy: Is there an elephant in the room?, Brachytherapy 9, 289-292; discussion 297-298 (2010). 10.1016/j.brachy. 2010.08.002
22. J. Crook, N. Patil, C. Ma, M. McLean, and J. Borg, Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy., Int. J. Radiat. Oncol., Biol., Phys. 77, 1079-1084 (2010). 10.1016/j.ijrobp.2009.06.040
23. D. Taussky, L. Austen, A. Toi, I. Yeung, T. Williams, S. Pearson, M. McLean, G. Pond, and J. Crook, Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion., Int. J. Radiat. Oncol., Biol., Phys. 62, 974-980 (2005). 10.1016/j.ijrobp.2004.12.012
24. O. Tanaka, S. Hayashi, M. Matsuo, M. Nakano, Y. Kubota, S. Maeda, K. Ohtakara, T. Deguchi, and H. Hoshi, MRI-based preplanning in low-dose-rate prostate brachytherapy., Radiother. Oncol. 88, 115-120 (2008). 10.1016/j.radonc.2007.09.012
25. O. Tanaka, S. Hayashi, M. Matsuo, K. Sakurai, M. Nakano, S. Maeda, K. Kajita, T. Deguchi, and H. Hoshi, Comparison of MRI-based and CTMRI fusion-based postimplant dosimetric analysis of prostate brachytherapy., Int. J. Radiat. Oncol., Biol., Phys. 66, 597-602 (2006). 10.1016/j.ijrobp.2006.06.023
26. S. Eggener, G. Salomon, P. T. Scardino, J. De la Rosette, T. J. Polascik, and S. Brewster, Focal therapy for prostate cancer: Possibilities and limitations., Eur. Urol. 58, 57-64 (2010). 10.1016/j.eururo.2010.03.034
27. S. E. Eggener, P. T. Scardino, P. R. Carroll, M. J. Zelefsky, O. Sartor, H. Hricak, T. M. Wheeler, S. W. Fine, J. Trachtenberg, M. A. Rubin, M. Ohori, K. Kuroiwa, M. Rossignol, L. Abenhaim, and International Task Force on Prostate Cancer and the Focal Lesion Paradigm, Focal therapy for localized prostate cancer: A critical appraisal of rationale and modalities., J. Urol. 178, 2260-2267 (2007). 10.1016/j.juro.2007.08.072
28. S. P. DiMaio and S. E. Salcudean, Needle insertion modeling and simulation., IEEE Trans. Rob. Autom. 19, 864-875 (2003). 10.1109/TRA.2003.817044
29. R. Alterovitz, J. Pouliot, R. Taschereau, I. C. Hsu, and K. Goldberg, Simulating needle insertion and radioactive seed implantation for prostate brachytherapy., Stud Health Technol. Inform. 94, 19-25 (2003).
30. N. Abolhassani, R. Patel, and M. Moallem, Needle insertion into soft tissue: A survey., Med. Eng. Phys. 29, 413-431 (2007). 10.1016/j.medengphy.2006. 07.003
31. R. J. Webster, III, J. Memisevic, and A. M. Okamura. Design considerations for robotic needle steering., Proceedings of the 2005 IEEE International Conference on Robotics and Automation, ICRA, 2005, pp. 3588-3594. 10.1109/ROBOT.2005.1570666
32. M. Moll and L. E. Kavraki, Path planning for minimal energy curves of constant length., IEEE Trans. Rob. Autom. 3, 2826-2831 (2004). 10.1109/ROBOT.2004.1307489
33. K. Damme and R. Wang, Curve interpolation with constrained length., Computing 54, 69-81 (1995). 10.1007/BF02238080
34. Z. Chen, N. Yue, X. Wang, K. B. Roberts, R. Peschel, and R. Nath, Dosimetric effects of edema in permanent prostate seed implants: A rigorous solution., Int. J. Radiat. Oncol., Biol., Phys. 47, 1405-1419 (2000). 10.1016/S0360-3016(00)00549-6
35. F. M. Waterman and A. P. Dicker, Impact of postimplant edema on V(100) and D(90) in prostate brachytherapy: Can implant quality be predicted on day 0?, Int. J. Radiat. Oncol., Biol., Phys. 53, 610-621 (2002). 10.1016/S0360-3016(02) 02751-7
36. F. M. Waterman, N. Yue, B. W. Corn, and A. P. Dicker, Edema associated with I-125 Or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: An analysis based on serial CT acquisition., Int. J.Radiat. Oncol., Biol., Phys. 41, 1069-1077 (1998). 10.1016/S0360-3016(98)00152-7
37. N. Usmani, N. Chng, I. Spadinger, and W. J. Morris, Lack of significant intraprostatic migration of stranded iodine-125 sources in prostate brachytherapy implants., Brachytherapy 10, 275-285 (2010). 10.1016/j.brachy. 2010.10.001